Eurofins Discovery Introduces Innovative DiscoveryAI SAFIRE: A New AI-Driven Platform for Drug Discovery Trained Using Proprietary Datasets
February 29 2024 - 1:15AM
Business Wire
Regulatory News:
Eurofins Discovery, part of the Eurofins (Paris:ERF) network of
laboratories and an industry-leading provider of products and
services for drug discovery research, today announces the launch of
DiscoveryAI SAFIRE (Suite of
ADMET Predictions
For In Silico Refinement and Evaluation). SAFIRE is an advanced platform
that leverages proprietary datasets, artificial intelligence (AI),
and machine learning (ML), offering a unique capability for
expediting discovery. SAFIRE is now available for customer use
through the Eurofins Discovery website.
Eurofins Discovery’s experienced informatics experts collected
vast, high-quality and diverse datasets that provide a unique
approach in predicting the ADMET (Absorption, Distribution,
Metabolism, Excretion and Toxicity) properties of molecules. It
sets a new standard in predictive analytics.
SAFIRE utilises data from Eurofins Discovery’s preeminent
BioPrint database, curated over years of meticulous research and
data accumulation. The result: a more powerful research tool
surpassing the limits that exist in other predictive systems
currently in the market, as demonstrated in a recent publication in
the Future Medical Chemistry journal.
Designed with end-users in mind, SAFIRE provides essential
features such as scoring functionality to aid in decision-making
and a comprehensive suite of predictive ADME models. It’s proven
effective in accelerating drug discovery projects from initial hit
discovery through to lead optimisation.
How does SAFIRE go beyond existing predictive system limits in
the market? Published results of AI advances demonstrated how
Eurofins Discovery’s models can be used to predict ADMET properties
of molecules quickly and efficiently, when trained with BioPrint
database proprietary data along with public datasets utilised by
the SAFIRE platform. This approach has proven improved model
performance as well as broadened the chemical space covered by the
models, achieving Matthews Correlation Coefficient values greater
than 0.4, and accuracies above 80%.
Eurofins Discovery’s experts keep SAFIRE dynamic with consistent
updates, enlargements of its chemical space, and the latest in AI
and ML innovations. For more details about SAFIRE’s benefits and
significant value to the drug discovery community, visit
eurofinsdiscovery.com/safire.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. The Eurofins network of companies
believes that it is a global leader in food, environment,
pharmaceutical and cosmetic product testing and in discovery
pharmacology, forensics, advanced material sciences and agroscience
contract research services. It is also one of the market leaders in
certain testing and laboratory services for genomics, and in the
support of clinical studies, as well as in biopharma contract
development and manufacturing. It also has a rapidly developing
presence in highly specialised and molecular clinical diagnostic
testing and in-vitro diagnostic products.
With ca. 62,000 staff across a decentralised and entrepreneurial
network of more than 900 laboratories in 62 countries, Eurofins
offers a portfolio of over 200,000 analytical methods to evaluate
the safety, identity, composition, authenticity, origin,
traceability and purity of a wide range of products, as well as
providing innovative clinical diagnostic testing services and
in-vitro diagnostic products.
Eurofins companies’ broad range of services are important for
the health and safety of people and our planet. The ongoing
investment to become fully digital and maintain the best network of
state-of-the-art laboratories and equipment supports our objective
to provide our customers with high-quality services, innovative
solutions and accurate results in the best possible turnaround time
(TAT). Eurofins companies are well positioned to support clients’
increasingly stringent quality and safety standards and the
increasing demands of regulatory authorities as well as the
evolving requirements of healthcare practitioners around the
world.
Eurofins has grown very strongly since its inception and its
strategy is to continue expanding its technology portfolio and its
geographic reach. Through R&D and acquisitions, the Group draws
on the latest developments in the field of biotechnology and
analytical chemistry to offer its clients unique analytical
solutions.
Shares in Eurofins Scientific are listed on the Euronext Paris
Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF
FP).
Until it has been lawfully made public widely by Eurofins
through approved distribution channels, this document contains
inside information for the purpose of Regulation (EU) 596/2014 of
the European Parliament and of the Council of 16 April 2014 on
market abuse, as amended.
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgment of
Eurofins Scientific’s management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantees can be made as to their completeness
or validity.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240228237935/en/
Notes to Editors:
For more information, please visit www.eurofins.com or
contact:
Investor Relations Eurofins Scientific SE Phone: +32 2 766 1620
E-mail: ir@sc.eurofinseu.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Apr 2024 to May 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From May 2023 to May 2024